Last reviewed 2026-05-31 · How we verify

Midazolam, ketamine

Midazolam, ketamine is a Benzodiazepine + NMDA receptor antagonist combination Small molecule drug developed by Universidade Federal de Goias. It is currently FDA-approved for Procedural sedation and analgesia, Emergency sedation, Anesthesia induction. Also known as: Dormire, Cristalia, Sao Paulo, Brazil, Ketamin S+, Cristalia, Sao Paulo, Brazil.

This is a combination of midazolam (a benzodiazepine GABA-A receptor agonist) and ketamine (an NMDA receptor antagonist) used together for sedation and anesthesia.

Midazolam is a small molecule that acts as a positive allosteric modulator of the GABA-A receptor, an anion channel. It is used in combination with other medications, such as fentanyl, for sedation and analgesia, and has been studied in various clinical trials for conditions including non-small cell lung cancer and laceration repair.

At a glance

Mechanism of action

Midazolam enhances inhibitory GABAergic neurotransmission in the central nervous system, producing sedation and anxiolysis. Ketamine blocks NMDA glutamate receptors, producing dissociative anesthesia and analgesia. The combination is used clinically to achieve rapid sedation with analgesic properties, commonly employed in procedural sedation and emergency medicine settings.

Approved indications

• Procedural sedation and analgesia
• Emergency sedation
• Anesthesia induction

Common side effects

• Respiratory depression
• Hypotension
• Dissociation/emergence reactions
• Dizziness
• Nausea

Key clinical trials

• Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
• Ketamine for Multiple Sclerosis Fatigue (PHASE2)
• The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delivery Under Spinal Anesthesia (NA)
• A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (PHASE3)
• Ketamine, SGB and Combination Treatment for TBI (PHASE2)
• Prospective IR-led Sedation Feasibility (PHASE1, PHASE2)
• Ketamine for Treatment-Resistant Bipolar Disorder (PHASE2)
• Comparative Assessment of Oral Premedication Regimens in Pediatric Ambulatory Surgery (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Midazolam, ketamine CI brief — competitive landscape report
• Midazolam, ketamine updates RSS · CI watch RSS
• Universidade Federal de Goias portfolio CI

Frequently asked questions about Midazolam, ketamine

Related

• Drug class: All Benzodiazepine + NMDA receptor antagonist combination drugs
• Target: All drugs targeting GABA-A receptor (midazolam); NMDA glutamate receptor (ketamine)
• Manufacturer: Universidade Federal de Goias — full pipeline
• Therapeutic area: All drugs in Anesthesia / Sedation
• Indication: Drugs for Procedural sedation and analgesia
• Indication: Drugs for Emergency sedation
• Indication: Drugs for Anesthesia induction
• Also known as: Dormire, Cristalia, Sao Paulo, Brazil, Ketamin S+, Cristalia, Sao Paulo, Brazil

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing